Phase 3 Readout
OGN: Phase 3 Topline: A Phase 3 Study of Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
October 1, 2026 · tapinarof. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 1, 2026
- Company
- Organon & Co. (OGN)
- Drug
- tapinarof
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3 Study of Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
- Company
- Organon & Co. (OGN)
- Drug
- tapinarof
- Indication
- Plaque Psoriasis